Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock
Portfolio Pulse from Vandana Singh
Stifel has upgraded Editas Medicine Inc (NASDAQ:EDIT) from Hold to Buy with a price target of $17, up from $9, citing progress in the company's sickle cell disease candidate, EDIT-301. The analysts also discussed the valuation disparity between Editas and CRISPR Therapeutics AG (NASDAQ:CRSP), and the potential benefits emerging from the IP dispute. Editas shares are up 11.30% at $7.70.
September 29, 2023 | 5:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel has upgraded Editas Medicine Inc (NASDAQ:EDIT) from Hold to Buy with a price target of $17, up from $9. This could lead to increased investor interest and a potential rise in the stock price.
The upgrade from Stifel could lead to increased investor interest in Editas Medicine Inc. The progress in the company's sickle cell disease candidate, EDIT-301, and the raised price target from $9 to $17 are positive indicators for the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
The analysts discussed the valuation disparity between Editas and CRISPR Therapeutics AG (NASDAQ:CRSP), and the potential benefits emerging from the IP dispute.
The discussion about the valuation disparity between Editas and CRISPR Therapeutics AG and the potential benefits emerging from the IP dispute could lead to increased scrutiny of CRISPR Therapeutics AG's valuation. However, the impact on the stock price is uncertain.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50